In the News
Offering Market Incentives to Address Antimicrobial Resistance
Washington, July 19, 2021
The Pasteur Act in Congress is designed to incentivize pharmaceutical companies to develop new antibiotics
Earlier this year, the Pew Trusts released a report that showed there were only 43 new antibiotics in development. Typically it takes 10 to 15 years from development to approval for antibiotics, but it only takes 2 years to develop bacterial resistance to new antibiotics.
This is compounded by the fact more than 2.8 million antibiotic-resistant infections occur in the United States and at least 35,000 people die as a result according to the US Centers for Disease Control and Prevention’s (CDC) Antibiotic Resistance Threats in the United States report.
While there is certainly a need for new therapies, there are significant barriers for development. With the process taking several years, many smaller companies end up dropping out of development. In addition, the market for reimbursement is low for antibiotics and further disincentivizes pharmaceutical companies from developing them.
The US federal government is looking to create incentives to encourage companies to develop new antibiotics. The US National Action Plan for Combating Antibiotic-Resistant Bacteria directed federal agencies to accelerate a response to antibiotic resistance and take action to expand the ability of our health care system to prevent, identify, and respond to the infection pandemic threat posed by antimicrobial resistance. Part of this plan was to increase and incentivize development of innovative antimicrobial drugs to treat resistant infections.
The Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act, is a bipartisan, bicameral piece of legislation aimed to incentivize innovative drug development targeting the most threatening infections, improve the appropriate use of antibiotics, and ensure domestic availability when needed. Initially introduced in Congress by U.S. Senators Michael Bennet (D-Colo.) and Todd Young (R-Ind.) in September of last year, Bennet and Young along with and Representatives Mike Doyle (D-Pa.) and Drew Ferguson (R-Ga.) reintroduced the bill in June.
The prospective bill if passed, would do the following:
Contagion spoke with Wes Kim, PhD, senior officer Antibiotic Resistance Project, Pew Trusts who provided further insights about the Pasteur Act, discussed the economic pull incentives to stimulate antibiotic development, and the role COVID-19 played in the antibiotic market.
We look forward to meeting with you and developing lasting relationships that can have a major impact on our district and beyond.
Washington, DC Office1032 Longworth House Office Building
Washington, DC 20515 202-225-5901
Newnan Office1601 E Hwy 34 Suite B
Newnan, GA 30265 770-683-2033